NCT04568863 - Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2020

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions

COVID-19SARS-CoV 2Coronavirus Infection

Interventions

DRUG

Melatonin intravenous

7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.

DRUG

Placebo intravenous

7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.

Trial Locations (1)

Hospital Universitario La Paz, Madrid